|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Seven Lessons I Learned Working at a Biotech Startupabout 4 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesabout 4 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsabout 4 years ago
Diversity in Action: Q&A With Reshma Kewalramaniabout 4 years ago
Diversity in Action: Q&A With Bob McMahonabout 4 years ago
A Dogged Devotionabout 4 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everabout 4 years ago
The Case for Elevating a Brand’s Price Propositionabout 4 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5